SPY384.24+0.35 0.09%
DIA311.87+0.10 0.03%
IXIC13,530.92+73.67 0.55%

Albireo Pharma shares are trading lower after the company announced its Phase 2 trial did not achieve proof-of-concept for other key NASH measures.

Benzinga · 08/18/2020 20:51